$RZLT News

Maxim Group Maintains Buy on Rezolute, Raises Price Target to $14

Citizens Upgrades Rezolute to Market Outperform, Announces $11 Price Target

Wedbush Maintains Outperform on Rezolute, Raises Price Target to $6

Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $5 Price Target

Rezolute Reports Mid-Study Results for Rare Hypoglycemia Treatment

Maxim Group Maintains Buy on Rezolute, Raises Price Target to $10

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute Q3 EPS $(0.16), Inline

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

Rezolute Presents Expanded Phase 3 Data Showing Ersodetug Delivers Significant; Sees Consistent Glycemic Improvements And Sustained Benefits In Congenital Hyperinsulinism Patients

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Rezolute Says Results From Phase 3 sunRIZE Study Of Ersodetug In Congenital HI Accepted For Oral Presentation At 2026 PES Annual Meeting

Rezolute: Caught Between Biology And Statistics, Initiating With Hold Rating

Rezolute: Sell Rating Despite FDA Feedback From Type B Meeting For Ersodetug

Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update

Rezolute shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform and raised its price target from $2 to $5.

Rezolute shares are trading higher after Wedbush upgraded the stock from Neutral to Outperform and raised its price target from $2 to $5.

Wedbush Upgrades Rezolute to Outperform, Raises Price Target to $5